Salarius Pharmaceuticals remains a pre-revenue clinical-stage entity with no commercial product, leaving its valuation entirely dependent on the success of its oncology research pipeline. The company faces significant financial headwinds, evidenced by an accum...
Price trend, volume and key moving averages
Trailing total returns as of 9/26/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Benchmark SLRX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Salarius Pharmaceuticals, Inc. (SLRX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.74 | $697.79K | -0.01 | — | — | -164.02% | — | |
| $33.30 | $6.87B | -12.02 | — | -7585.86% | -69.59% | — | |
| $11.62 | $371.82M | 5.05 | 6774.96% | -553.88% | -21.4% | — | |
| $4.83 | $196.09M | 3.96 | 55.25% | 45.97% | 10.97% | — | |
| $8.54 | $355.63M | -2511.76 | 10.37% | 69.76% | — | — | |
| $1.21 | $72.69M | -2.15 | — | — | -53.14% | — |
Salarius Pharmaceuticals, Inc. (SLRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when SLRX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Salarius Pharmaceuticals, Inc. (SLRX) stock FAQ — growth, dividends, profitability & financials explained
Salarius Pharmaceuticals, Inc. (SLRX) reported a net loss of $5.0M for fiscal year 2024.
Salarius Pharmaceuticals, Inc. (SLRX) has a return on equity (ROE) of -164.0%. Negative ROE indicates the company is unprofitable.
Salarius Pharmaceuticals, Inc. (SLRX) had negative free cash flow of $4.4M in fiscal year 2024, likely due to heavy capital investments.
